Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

Journal of Clinical Oncology

Volumn 22, Issue 5, 2004, Pages 909-918

  Atkins, Michael B ^a   Hidalgo, Manuel ^a   Stadler, Walter M ^a   Logan, Theodore F ^a   Dutcher, Janice P ^a   Hudes, Gary R ^a   Park, Young ^a   Liou, Song Heng ^a   Marshall, Bonnie ^a   Boni, Joseph P ^a   Dukart, Gary ^a   Sherman, Matthew L ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TEMSIROLIMUS; DRUG DERIVATIVE; RAPAMYCIN;

ANEMIA; ARTICLE; ASTHENIA; BLOOD SAMPLING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPOPHOSPHATEMIA; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MAMMAL; MUCOSA INFLAMMATION; NAUSEA; PAPULE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RISK ASSESSMENT; TOXICITY; TUMOR GROWTH; AGED; BIOAVAILABILITY; CANCER INVASION; CANCER STAGING; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DRUG ADMINISTRATION; DRUG ANTAGONISM; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY TUMOR; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROBABILITY; PROGNOSIS; SALVAGE THERAPY; SURVIVAL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BIOLOGICAL AVAILABILITY; CARCINOMA, RENAL CELL; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROBABILITY; PROGNOSIS; RISK ASSESSMENT; SALVAGE THERAPY; SIROLIMUS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 1542398693     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.08.185     Document Type: Article

References (51)

1. Linehan WM, Zbar B, Bates SE, et al: Cancer of the kidney and ureter, in DeVita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles & Practice of Oncology. Philadelphia, PA, Lippincott, Williams & Wilkins, 2001, pp 1362-1396
2. Jemal A, Thomas A, Murray T, et al: Cancer statistics, 2002. CA Cancer J Clin 52:23-47, 2002
3. Amato RJ: Chemotherapy for renal cell carcinoma. Semin Oncol 27:177-186, 2000
4. Fisher RI, Rosenberg SA, Fyfe G: Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 6:S55-S57, 2000 (suppl 1)
5. Fyfe G, Fisher RI, Rosenberg SA, et al: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13:688-696, 1995
6. Porzsolt F, Messerer D, Hautmann R, et al: Treatment of advanced renal cell cancer with recombinant interferon alpha as a single agent and in combination with medroxyprogesterone acetate: A randomized multicenter trial. J Cancer Res Clin Oncol 114:95-100, 1988
7. Steineck G, Strander H, Carbin BE, et al: Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma: A randomized trial. Acta Oncol 29:155-162, 1990
8. Creagan ET, Twito DI, Johansson SL, et al: A randomized prospective assessment of recombinant leukocyte A human interferon with or without aspirin in advanced renal adenocarcinoma. J Clin Oncol 9:2104-2109, 1991
9. Sagaster P, Micksche M, Flamm J, et al: Randomised study using IFN-alpha versus IFN-alpha plus coumarin and cimetidine for treatment of advanced renal cell cancer. Ann Oncol 6:999-1003, 1995
10. Medical Research Council Renal Cancer Collaborators: Interferon-alpha and survival in metastatic renal carcinoma: Early study results of a randomized controlled trial. Lancet 353:14-17, 1999
11. Neidhart JA, Anderson SA, Harris JE, et al: Vinblastine fails to improve response of renal cancer to interferon alfa-n1: High response rate in patients with pulmonary metastases. J Clin Oncol 9:832-836, 1991
12. De Mulder PH, Oosterhof G, Bouffioux C, et al: EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma: The EORTC Genitourinary Group. Br J Cancer 71:371-375, 1995
13. Fossa SD, Martinelli G, Otto U, et al: Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: Results of a European multi-center phase III study. Ann Oncol 3:301-305, 1992
14. Negrier S, Escudier B, Lasset C, et al: Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma: Groupe Francais d'Immunotherapie. N Engl J Med 338:1272-1278, 1998
15. Kriegmair M, Oberneder R, Hofstetter A: Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma. Urology 45:758-762, 1995
16. Pyrhonen S, Salminen E, Ruutu M, et al: Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 17:2859-2867, 1999
17. Boccardo F, Rubagotti A, Canobbio L, et al: Interleukin-2, interferon-alpha and interleukin-2 plus interferon-alpha in renal cell carcinoma: A randomized phase II trial. Tumori 84:534-539, 1998
18. McDermott D, Flaherty L, Clark J: A randomized phase III trial of high-dose interleukin (HD IL-2) versus subcutaneous (SC) IL2/interferon (IFN) in patients with metastatic renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 20:172a, 2001 (abstr 685)
19. Skotnicki JS, Leone CL, Smith AL: Design, synthesis, and biological evaluation of C-42 hydroxyesters of rapamycin: The identification of CCI-779. Clin Cancer Res 7:37495-37505, 2001
20. Dudkin L, Dilling MB, Cheshire PJ, et al: Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res 7:1758-1764, 2001
21. Neshat MS, Mellinghoff IK, Tran C, et al: Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 98:10314-10319, 2001
22. Yu K, Toral-Barza L, Discafani C, et al: MTOR, a novel target in breast cancer: The effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 8:249-258, 2001
23. Gibbons JJ, Discafani C, Peterson R: The effect of CCI-779, a novel macrolide anti-tumor agent, on growth of human tumor cells in vitro and in nude mouse xenografts in vivo. Proc Am Assoc Cancer Res 40:301, 1999 (abstr 1000)
24. Vogt PK: Pl 3-kinase, mTOR, protein synthesis and cancer. Trends Mol Med 7:482-484, 2001
25. Podsypanina K, Lee RT, Politis C. et al: An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc Natl Acad Sci U S A 98:10320-10325, 2001
26. Brenner W, Farber G, Herget T, et al: Loss of tumor suppressor protein PTEN during renal carcinogenesis. Int J Cancer 99:53-57, 2002
27. Velichovic M, Delahunt B, McIver B, et al: Intragenic PTEN/MMAC1 loss of heterozygosity in conventional (clear-cell) renal cell carcinoma is associated with poor patient prognosis. Mod Pathol 15:479-485, 2002
28. Tee AR, Fingar DC, Manning BD, et al: Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci U S A 99:13571-13576, 2002
29. Manning BD, Tee AR, Logsdon MN, et al: Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell 10:151-162, 2002
30. Dan HC, Sun M, Yang L, et al: Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J Biol Chem 277:35364-35370, 2002
31. Ohh M, Park CW, Ivan M, et al: Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2:423-427, 2000
32. Iliopoulos O, Levy AP, Jiang C, et al: Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A 93:10595-10599, 1996
33. Hudson CC, Liu M, Chiang GG, et al: Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 22:7004-7014, 2002
34. Turner KJ, Moore JW, Jones A, et al: Expression of hypoxia-inducible factors in human renal cancer: Relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res 62:2957-2961, 2002
35. Raymond E, Alexandre J, Depenbrock H, et al: CCI-779, a rapamycin analog with antitumor activity: A phase 1 study utilizing a weekly schedule. Proc Am Soc Clin Oncol 19:187a, 2000 (abstr 728)
36. Snow RM, Schellhammer PF: Spontaneous regression of metastatic renal cell carcinoma. Urology 20:177-181, 1982
37. Cleave ME, Elhilali M, Fradet Y, et al: Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. N Engl J Med 338:1265-1271, 1998
38. Punt C, Boni J, Bruntsch U, et al: Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. Ann Oncol 14:931-937, 2003
39. Jusko WJ: Guidelines for collection and analysis of pharmacokinetic data, in Evans WE, Schentag JJ, Jusko WJ (eds): Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. Vancouver, WA, Applied Thrapeutics Inc, 1992, pp 1-43
40. Motzer RJ, Bacik J, Murphy BA, et al: Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20:289-296, 2002
41. Yang JC, Haworth L, Sherry RM, et al: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434, 2003
42. Daliani DD, Papandreou CN, Thall PF, et al: A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma. Cancer 95:758-765, 2002
43. Stebbing J, Benson C, Eisen T, et al: The treatment of advanced renal cell cancer with high-dose oral thalidomide. Br J Cancer 85:953-958, 2001
44. Motzer RJ, Berg W, Ginsberg M, et al: Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J Clin Oncol 20:302-306, 2002
45. Gollob JA, Mier JW, Veenstra K, et al: Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: Ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res 6:1678-1692, 2000
46. Kugler A, Stuhler G, Walden P, et al: Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 6:332-336, 2000
47. Holtl L, Zelle-Rieser C, Gander H: Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res 8:3369-3376, 2002
48. Childs R, Chernoff A, Contentin N, et al: Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343:750-758, 2000
49. Dutcher JP, Hudes G, Motzer RJ, et al: Preliminary report of a phase 1 study of intravenous (IV) CCI-779 given in combination with interferon-alpha (IFN) to patients with advanced renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 22:213, 2003 (abstr 85F)
50. Taha C, Liu Z, Jin J, et al: Opposite translational control of GLUT1 and GLUT4 glucose transporter mRNAs in response to insulin: Role of mammalian target of rapamycin, protein kinase b, and phosphatidylinositol 3-kinase in GLUT1 mRNA translation. J Biol Chem 274:33085-33091, 1999
51. Huffman TA, Mothe-Satney I, Lawrence JC Jr: Insulin-stimulated phosphorylation of lipin mediated by the mammalian target of rapamycin. Proc Natl Acad Sci U S A 99:1047-1052, 2002